Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
ProShares Ultra Nasdaq Biotechnology
ETF
BIB
Payout Change
Pending
Price as of:
$56.84
+1.74
+3.16%
primary theme
Leveraged Equity
BIB (ETF)
ProShares Ultra Nasdaq Biotechnology
Payout Change
Pending
Price as of:
$56.84
+1.74
+3.16%
primary theme
Leveraged Equity
BIB (ETF)
ProShares Ultra Nasdaq Biotechnology
Payout Change
Pending
Price as of:
$56.84
+1.74
+3.16%
primary theme
Leveraged Equity
Name
As of 11/22/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
0.4%
1 yr return
30.0%
3 Yr Avg Return
-11.9%
5 Yr Avg Return
0.2%
Net Assets
$88.3 M
Holdings in Top 10
51.2%
52 WEEK LOW AND HIGH
$55.1
$43.23
$68.49
Expenses
OPERATING FEES
Expense Ratio 1.14%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 11/22/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
BIB - Profile
Distributions
- YTD Total Return 0.4%
- 3 Yr Annualized Total Return -11.9%
- 5 Yr Annualized Total Return 0.2%
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.58%
- Dividend Yield 1.1%
- Dividend Distribution Frequency Quarterly
Fund Details
-
Legal NameProShares Ultra Nasdaq Biotechnology
-
Fund Family NameProShares Trust
-
Inception DateApr 08, 2010
-
Shares Outstanding1950000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerMichael Neches
Fund Description
The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target.The Index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. The Index includes companies listed on the Nasdaq Global Select Market or the Nasdaq Global Market (which include both U.S. and non-U.S. companies) that are included in the biotechnology or pharmaceuticals subsectors, according to the Industry Classification Benchmark. The biotechnology and pharmaceutical subsectors include companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development and manufacturers of prescription or over-the-counter drugs. Companies are selected based on market capitalization and liquidity. Selected companies are then weighted based on market capitalization. The Index’s composition and the assigned weights are reevaluated every December, with additional weight adjustments occurring in March, June, and September. The Index is constructed and maintained by Nasdaq Inc. More information about the Index can be found using the Bloomberg ticker symbol “NBI.”Under normal circumstances, the Fund will obtain leveraged exposure to at least 80% of its total assets in components of the Index or in instruments with similar economic characteristics.The Fund will invest principally in the financial instruments listed below.●Equity Securities — Common stock issued by public companies.●Derivatives — Financial instruments whose value is derived from the value of an underlying asset or rate, such as stocks, bonds, ETFs, interest rates or indexes. These derivatives principally include:○Swap Agreements — Contracts entered into primarily with major global financial institutions for a specified period ranging from a day to more than one year. In a standard swap transaction, two parties agree to exchange or “swap” payments based on the change in value of an underlying asset or benchmark. For example, two parties may agree to exchange the return (or differentials in rates of returns) earned or realized on a particular investment or instrument.●Money Market Instruments — The Fund expects that any cash balances maintained in connection with its use of derivatives will typically be held in high quality, short-term money market instruments, for example:○U.S. Treasury Bills — U.S. government securities that have initial maturities of one year or less, and are supported by the full faith and credit of the U.S. government.○Repurchase Agreements — Contracts in which a seller of securities, usually U.S. government securities or other money market instruments, agrees to buy the securities back at a specified time and price.ProShare Advisors uses a mathematical approach to investing in which it determines the type, quantity and mix of investment positions that it believes, in combination, the Fund should hold to produce daily returns consistent with the Daily Target. For these purposes a day is measured from the time of one net asset value (“NAV”) calculation to the next.The Fund seeks to remain fully invested at all times in financial instruments that, in combination, provide leveraged exposure consistent with the investment objective, without regard to market conditions, trends or direction. However, the Fund may invest in or gain exposure to only a representative sample of the securities in the Index or to securities not contained in the Index or in financial instruments, with the intent of obtaining leveraged exposure consistent with the investment objective.The Fund seeks to rebalance its portfolio each day so that its exposure to the Index is consistent with the Daily Target. The Index’s movements during the day will affect whether the Fund’s portfolio needs to be rebalanced. For example, if the Index has risen on a given day, net assets of the Fund should rise (assuming there were no Creation Unit redemptions). As a result, the Fund’s exposure will need to be increased. Conversely, if the Index has fallen on a given day, net assets of the Fund should fall (assuming there were no Creation Units issued). As a result, the Fund’s exposure will need to be decreased.Please see “Investment Objectives, Principal Investment Strategies and Related Risks” in the Fund’s Prospectus for additional details.
Read More
BIB - Performance
Return Ranking - Trailing
| Period | BIB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 0.4% | -69.2% | 140.0% | 89.24% |
| 1 Yr | 30.0% | -59.2% | 185.5% | 69.62% |
| 3 Yr | -11.9%* | -50.2% | 35.6% | 85.44% |
| 5 Yr | 0.2%* | -40.0% | 58.2% | 74.68% |
| 10 Yr | -0.8%* | -37.5% | 43.2% | 83.33% |
* Annualized
Return Ranking - Calendar
| Period | BIB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -1.1% | -56.9% | 257.9% | 82.28% |
| 2022 | -28.9% | -91.0% | 124.5% | 31.01% |
| 2021 | -6.0% | -79.4% | 168.2% | 79.75% |
| 2020 | 39.8% | -97.4% | 132.6% | 23.42% |
| 2019 | 46.7% | -53.1% | 229.8% | 44.23% |
Total Return Ranking - Trailing
| Period | BIB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 0.4% | -69.2% | 140.0% | 89.24% |
| 1 Yr | 30.0% | -59.2% | 185.5% | 69.62% |
| 3 Yr | -11.9%* | -50.2% | 35.6% | 85.44% |
| 5 Yr | 0.2%* | -40.0% | 58.2% | 74.68% |
| 10 Yr | -0.8%* | -37.5% | 43.2% | 83.33% |
* Annualized
Total Return Ranking - Calendar
| Period | BIB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -1.1% | -55.8% | 259.6% | 82.91% |
| 2022 | -28.8% | -91.0% | 130.7% | 31.01% |
| 2021 | -6.0% | -79.4% | 168.2% | 84.18% |
| 2020 | 39.8% | -97.4% | 132.6% | 24.05% |
| 2019 | 46.7% | -52.7% | 231.9% | 49.36% |
BIB - Holdings
Concentration Analysis
| BIB | Category Low | Category High | BIB % Rank | |
|---|---|---|---|---|
| Net Assets | 88.3 M | 1.5 M | 22.2 B | 38.32% |
| Number of Holdings | 232 | 5 | 2009 | 21.60% |
| Net Assets in Top 10 | 48.3 M | 1.08 M | 9.23 B | 39.51% |
| Weighting of Top 10 | 51.22% | 13.9% | 185.3% | 64.20% |
Top 10 Holdings
- U.S. Treasury Bills 10.47%
- Gilead Sciences, Inc. 5.81%
- Regeneron Pharmaceuticals, Inc. 5.71%
- Amgen, Inc. 5.16%
- Vertex Pharmaceuticals, Inc. 5.15%
- Total Return Swap 5.14%
- Repurchase Agreement 4.42%
- Repurchase Agreement 3.41%
- Total Return Swap 3.30%
- AstraZeneca plc 2.65%
Asset Allocation
| Weighting | Return Low | Return High | BIB % Rank | |
|---|---|---|---|---|
| Stocks | 65.37% | 0.00% | 375.12% | 59.88% |
| Other | 22.40% | -7.39% | 99.69% | 38.89% |
| Cash | 13.25% | 0.00% | 104.72% | 32.72% |
| Preferred Stocks | 0.00% | 0.00% | 1.99% | 51.85% |
| Convertible Bonds | 0.00% | 0.00% | 0.32% | 56.17% |
| Bonds | 0.00% | 0.00% | 37.59% | 61.11% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | BIB % Rank | |
|---|---|---|---|---|
| Utilities | 0.00% | 0.00% | 100.00% | 60.14% |
| Technology | 0.00% | 0.00% | 100.00% | 76.92% |
| Real Estate | 0.00% | 0.00% | 100.00% | 55.24% |
| Industrials | 0.00% | 0.00% | 100.00% | 77.62% |
| Healthcare | 0.00% | 0.00% | 100.00% | 4.20% |
| Financial Services | 0.00% | 0.00% | 100.00% | 73.43% |
| Energy | 0.00% | 0.00% | 100.00% | 63.64% |
| Communication Services | 0.00% | 0.00% | 100.00% | 76.92% |
| Consumer Defense | 0.00% | 0.00% | 52.46% | 69.93% |
| Consumer Cyclical | 0.00% | 0.00% | 94.15% | 75.52% |
| Basic Materials | 0.00% | 0.00% | 100.00% | 52.45% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | BIB % Rank | |
|---|---|---|---|---|
| US | 65.37% | 0.00% | 375.12% | 59.88% |
| Non US | 0.00% | 0.00% | 20.00% | 51.23% |
BIB - Expenses
Operational Fees
| BIB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.14% | 0.68% | 5.63% | 76.58% |
| Management Fee | 0.75% | 0.00% | 0.95% | 44.91% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| BIB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 4.75% | 4.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| BIB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | N/A | N/A | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| BIB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | N/A | 0.00% | 266.00% | 23.31% |
BIB - Distributions
Dividend Yield Analysis
| BIB | Category Low | Category High | BIB % Rank | |
|---|---|---|---|---|
| Dividend Yield | 1.08% | 0.00% | 18.26% | 74.85% |
Dividend Distribution Analysis
| BIB | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Quarterly | Annually | Monthly | Quarterly |
Net Income Ratio Analysis
| BIB | Category Low | Category High | BIB % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.58% | -2.77% | 2.92% | 50.00% |
Capital Gain Distribution Analysis
| BIB | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Sep 25, 2024 | $0.153 | OrdinaryDividend |
| Jun 26, 2024 | $0.265 | OrdinaryDividend |
| Mar 20, 2024 | $0.040 | OrdinaryDividend |
| Dec 20, 2023 | $0.038 | OrdinaryDividend |
| Dec 22, 2022 | $0.020 | OrdinaryDividend |
| Sep 21, 2010 | $0.011 | OrdinaryDividend |
BIB - Fund Manager Analysis
Managers
Michael Neches
Start Date
Tenure
Tenure Rank
Oct 01, 2013
8.67
8.7%
Michael Neches joined ProShare Advisors in 2000, and presently serves as a Senior Portfolio Manager. He previously served as the Senior Portfolio Manager responsible for the company’s commodities desk for two years, as a Portfolio Manager and team lead, as an Associate Portfolio Manager and as a Portfolio Analyst. Mr. Neches earned a Bachelor of Science in Finance from the University of Maryland, College Park and an MBA from Georgetown University.
Tarak Davé
Start Date
Tenure
Tenure Rank
Apr 30, 2018
4.09
4.1%
Tarak Dave ProFund Advisors LLC: Portfolio Manager since March 2018, Associate Portfolio Manager from November 2015 to March 2018, Senior Portfolio Analyst from May 2014 to October 2015 and Portfolio Analyst from April 2011 to April 2014.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 1.79 | 28.9 | 9.84 | 8.67 |
